Vitamin D Is a Nuclear Hormone: The VDR Mechanism
The classification of vitamin D as a "vitamin" is historically misleading. Vitamins are organic compounds required from the diet because the body cannot synthesize them. Vitamin D, under conditions of adequate sun exposure, is synthesized endogenously from 7-dehydrocholesterol in the skin — functioning as a steroid hormone, not a dietary micronutrient in the classical sense.
The signaling pathway:
- Solar UVB (290–315 nm) strikes 7-dehydrocholesterol in the dermis, producing previtamin D3, which thermally isomerizes to cholecalciferol (vitamin D3) within 24 hours.
- D3 is hydroxylated in the liver by CYP2R1 (and CYP27A1) to produce 25-hydroxyvitamin D (25(OH)D, calcidiol) — the major circulating form and the form measured in blood tests. Half-life: approximately 2–3 weeks.
- 25(OH)D is hydroxylated in the kidney by CYP27B1 to produce 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol) — the biologically active hormone. Also produced locally in immune cells, gut epithelium, and other tissues. Half-life: approximately 4–6 hours.
- 1,25(OH)2D3 binds to VDR (Vitamin D Receptor) in the cytoplasm. The VDR-ligand complex heterodimerizes with RXR (Retinoid X Receptor) and translocates to the nucleus, binding vitamin D response elements (VDREs) — hexameric direct repeats in gene promoters. This activates or represses transcription of thousands of target genes.
VDR is expressed in: T cells (all subtypes), B cells, macrophages, dendritic cells, natural killer cells, intestinal epithelial cells, colonocytes, neurons, cardiomyocytes, pancreatic beta cells, and most other human cell types. This ubiquity explains why vitamin D deficiency has pleiotropic systemic effects beyond bone metabolism.
Holick 2007 and the Global Deficiency Landscape
Michael Holick's 2007 review in the New England Journal of Medicine synthesized the epidemiological and mechanistic case for widespread vitamin D deficiency as a public health crisis. Key findings:
- At latitudes above 35°N (roughly Chicago, Madrid, Seoul), from October through March, solar angle is insufficient to produce any vitamin D3 in the skin regardless of sun exposure duration — the UVB photons are absorbed by the atmosphere
- Sunscreen with SPF 30 reduces cutaneous vitamin D3 production by approximately 95%
- Skin pigmentation: melanin competes with 7-dehydrocholesterol for UVB photons; darker skin requires 3–10× longer sun exposure to produce equivalent vitamin D3
- The IOM "sufficient" threshold of 20 ng/mL was set for bone health outcomes only; for non-skeletal outcomes (immune function, cancer risk, autoimmunity, cardiovascular), the evidence base for higher thresholds (30–60 ng/mL) is substantial
- Dietary sources are negligible: fatty fish provides 300–500 IU/serving, fortified milk 100 IU/cup — achieving the 2,000–5,000 IU/day associated with serum adequacy from food alone is not feasible for most people
Immune Modulation: The Th17/Treg Balance
The most clinically significant immune action of 1,25(OH)2D3 is its role as a Th17 suppressor and Treg promoter — directly relevant to autoimmune disease risk.
T helper 17 (Th17) cells produce IL-17, IL-22, and other pro-inflammatory cytokines that drive autoimmune inflammation (the primary pathogenic cell type in multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease). Regulatory T cells (Tregs, expressing FOXP3) suppress Th17 and other effector T cells, maintaining immune tolerance.
VDR signaling in T cells:
- Suppresses IL-17 gene transcription directly via VDREs in the IL-17 promoter
- Inhibits RORC (RORγt), the master transcription factor for Th17 differentiation
- Upregulates FOXP3, promoting Treg differentiation from naive T cells
- Suppresses dendritic cell maturation, reducing antigen presentation capacity and T cell activation
Cantorna 2014 (Mucosal Immunology) showed that VDR-knockout mice develop exaggerated gut inflammation after pathogen challenge — establishing that intestinal VDR signaling is a non-redundant component of intestinal immune homeostasis.
Gut Barrier and VDR: The IBD Connection
VDR is highly expressed in intestinal epithelial cells (IECs). Its functions in the gut include:
- Tight junction regulation: VDR activation upregulates claudin-2 and occludin expression, promoting tight junction integrity and reducing intestinal permeability ("leaky gut")
- Antimicrobial peptide production: Cathelicidins and defensins are VDR target genes — reducing pathogen colonization of the gut mucosa
- Mucosal repair: VDR promotes IEC proliferation after injury via Wnt/β-catenin pathway interactions
The IBD connection: genome-wide association studies (GWAS) have identified VDR and genes in the vitamin D activation pathway as IBD susceptibility loci. Patients with Crohn's disease and ulcerative colitis have significantly lower serum 25(OH)D than matched controls, and disease activity inversely correlates with vitamin D status. Whether this is cause or effect (active inflammation may reduce vitamin D absorption and promote catabolism) remains debated — but the mechanistic case for VDR in gut barrier maintenance is strong.
| Study | Population / Design | Vitamin D Status | Finding |
|---|---|---|---|
| Holick 2007 (NEJM review) | Global epidemiology synthesis | 25(OH)D below 20 ng/mL | 1B+ people deficient; skin synthesis impossible Nov–Mar above 35°N latitude; dietary sources inadequate |
| Munger et al. 2006 (JAMA) | N=187,563 nurses, 20-year prospective | 25(OH)D ≥40 ng/mL vs. <20 ng/mL | −40% relative risk of MS; dose-response relationship; strongest in highest quintile |
| Cantorna et al. 2014 (Mucosal Immunol) | VDR-knockout mouse model | No functional VDR | Exaggerated gut inflammation; impaired Treg generation; disrupted tight junctions |
| Hossein-nezhad et al. 2013 (PLOS One) | N=10 healthy adults, RCT supplement vs placebo | Before vs. after achieving 25(OH)D >40 ng/mL | 2,000+ gene expression changes in peripheral blood; immune, inflammatory, and metabolic pathways |
| Grant 2016 (Dermato-Endocrinology, meta-analysis) | 25 vitamin D RCTs and observational studies | Various supplementation protocols | Cancer mortality reduced by ~13%; all-cause mortality reduced by ~6% in supplemented groups vs. placebo |
Testing and Dosing: The Math of Vitamin D Sufficiency
The blood test that matters: 25-hydroxyvitamin D [25(OH)D], not 1,25(OH)2D3. The active form (1,25(OH)2D3) has a short half-life, is tightly regulated, and is not a reliable indicator of whole-body vitamin D status. 25(OH)D has a half-life of 2–3 weeks and accurately reflects cumulative stores.
Target ranges (contested; Holick functional medicine consensus vs. IOM bone-health threshold):
- Deficient: below 20 ng/mL — universal clinical agreement; bone health impaired, parathyroid hormone (PTH) elevated compensatorily
- Insufficient: 20–30 ng/mL — IOM "sufficient for bone"; immune, cancer, and autoimmune literature suggests inadequate
- Sufficient (functional): 40–60 ng/mL — Holick target; associated with reduced MS, cancer, cardiovascular risk in observational literature
- Toxicity threshold: above 150 ng/mL — hypercalcemia risk; not achievable from sun or food alone; requires extremely high supplementation doses over extended periods
Dosing math: approximately 100 IU/day of vitamin D3 raises serum 25(OH)D by ~1 ng/mL at steady state. This is an average — varies significantly by body weight, gut absorption, baseline level, and VDR polymorphisms. Practical implications:
- To raise from 20 ng/mL to 50 ng/mL: requires an additional ~3,000 IU/day (30 ng/mL × 100 IU per ng/mL)
- Standard doses: 1,000–2,000 IU/day (supplementing from food/sun baseline) → modest improvement. 4,000–5,000 IU/day (therapeutic) → more reliably reaches 40–60 ng/mL
- The Endocrine Society's tolerable upper intake level is 10,000 IU/day for adults; doses up to 4,000 IU/day are considered safe for long-term supplementation without regular testing
Critical co-factor: vitamin K2 (MK-7). Vitamin D increases intestinal calcium absorption. Without adequate vitamin K2, activated Matrix Gla Protein (MGP) — which normally prevents calcium deposition in soft tissues — may be undersupplied. K2 MK-7 (menaquinone-7 from fermented foods or supplementation) activates MGP and osteocalcin, directing calcium to bone rather than arterial walls. High-dose vitamin D supplementation without K2 is not recommended in adults with cardiovascular risk factors.
Evidence-Based Vitamin D Protocol
- Test first: A 25(OH)D blood test (standard lipid panel add-on; typically $30–50 without insurance) determines your baseline and allows rational dosing. Supplementing blind at 2,000 IU may be inadequate for someone at 15 ng/mL; unnecessary for someone already at 55 ng/mL.
- Dose by baseline: Below 20 ng/mL → 5,000 IU D3/day for 3 months, then retest. 20–30 ng/mL → 3,000–4,000 IU/day. Above 30 ng/mL → 2,000 IU/day maintenance. Retest every 6 months while adjusting; once stable, annually.
- Form: D3 (cholecalciferol) raises serum 25(OH)D approximately 3× more effectively than D2 (ergocalciferol, plant-derived). Use D3 exclusively for supplementation.
- Co-supplementation: Vitamin K2 as MK-7 (100–200 mcg/day) with all doses above 2,000 IU D3. Magnesium (glycinate or malate, 300–400 mg/day) — multiple steps in the vitamin D activation pathway require Mg-dependent enzymes; deficiency impairs both conversion and receptor signaling.
- Absorption: Vitamin D3 is fat-soluble — take with a meal containing fat. Taking it on an empty stomach reduces absorption by approximately 50% compared to taking with a fat-containing meal.
- Gut health connection: Inflammatory bowel disease, fat malabsorption syndromes (Crohn's, celiac), and post-bariatric surgery states significantly impair D3 absorption; higher doses or alternative routes (sublingual D3 oil) may be necessary.
Recommended Products (Amazon)
Combined D3/K2 MK-7 formulations simplify the protocol. Look for at least 100 mcg MK-7 per serving and D3 (not D2). Thorne, Jarrow, and Life Extension make well-regarded formulations with third-party testing. Softgel forms in olive oil or MCT oil provide superior absorption vs. dry powder capsules.